Access Pharmaceuticals initiates Stage I/II dosage escalating study for Thiarabine Access Pharmaceuticals, Inc. , today announced it provides initiated a Phase I/II dose-escalating research of its proprietary, anti-cancer medication, Thiarabine, a nucleoside analog for individuals with hematologic malignancies . The planned program is being led by Hagop Kantarjian, M.D., Chair of the Department of Leukemia at The University of Texas MD Anderson Malignancy Center in Houston, Texas. Related StoriesNew antenna-like device makes breast cancer medical procedures less complicated for surgeonsViralytics enters into clinical trial collaboration contract with MSDNew RNA test of blood platelets may be used to detect location of malignancy We are very happy to possess Dr.The selections were predicated on a genuine number of criteria, including a mid-level position in informatics in a healthcare setting, a current permit to practice as a registered nurse, and the capability to make a difference as a head in neuro-scientific informatics. This inaugural plan aims to build up leaders capable of assuming nationwide leadership positions in an informatics-related organization. Both emerging leaders selected are: Ellen Makar, RN-BC, MSN, of Yale New Haven Wellness Program, Conn.; and Sandra Ng, RN-BC, MSN, UCSF Medical Center, part of the University of California, San Francisco. ANI and its own Nursing Informatics Emerging Leaders Program are jointly supported by the American Medical Informatics Association and the Health care Information and Management Systems Society .